Interpretation of laboratory results of elderly subjects: Effect of age or aging;Interprétation des examens de laboratoire chez la personne âgée : effet de l'âge ou du vieillissement

Annales Pharmaceutiques Francaises

Volumn 67, Issue 3, 2009, Pages 173-181

  Henny, J ^a  

^a Centre de Medecine Preventive   (France)

Author keywords

Aging; Decision limits; Elderly; Reference values

Indexed keywords

ADULT; AGE; AGED; AGING; CHRONIC DISEASE; CLINICAL DECISION MAKING; DATA BASE; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; LABORATORY TEST; MALE; REFERENCE VALUE; SHORT SURVEY;

AGING; BIOLOGICAL MARKERS; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PROSTATE-SPECIFIC ANTIGEN; REFERENCE STANDARDS;

EID: 68649114540     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2009.02.001     Document Type: Short Survey

References (49)

1. OMS. Vieillir en restant actif - Cadre d'orientation [serial online] 2002 Apr. Available from: URL: http://whqlibdoc.who.int/hq/2002/WHO_NMH_NPH_02.8.pdf.
2. Tubiana M. Le bien vieillir : la révolution de l'âge (2003), De Fallois, Paris
3. Baker G.T., and Sprott R.L. Biomarkers of aging. Exp Gerontol 23 (1988) 223-239
4. Johnson T.E. Recent results: biomarkers of aging 41 (2006) 1243-1246
5. Tietz N.W., Shuey D.F., and Wekstein D.R. Laboratory values in fit aging individuals - Sexagenarians through centenarians. Clin Chem 38 (1992) 1167-1185
6. Garry P.J., Hunt W.C., Vanderjagt D.J., and Rhyne R.L. Clinical chemistry reference intervals for healthy elderly subjects. Am J Clin Nutr 50 (1989) 1219-1230
7. Fraser C.G., Cummings S.T., Wilkinson S.P., Neville R.G., Knox J.D.E., Ho O., et al. Biological variability of 26 clinical chemistry analytes in elderly people. Clin Chem 35 (1989) 783-786
8. Kallner A., Gustavsson E., and Hendig E. Can age and sex related reference intervals be derived for non-healthy and non-diseased individuals from results of measurements in primary health care?. Clin Chem Lab Med 38 (2000) 633-654
9. Huber K.R., Mostafaie N., Stangl G., Worofka B., Kittl E., Hofmann J., et al. Clinical chemistry reference values for 75-year-old apparently healthy persons. Clin Chem Lab Med 44 (2006) 1355-1360
10. In: Siest G., Henny J., and Schiele F. (Eds). Références en biologie clinique (1990), Elsevier, Paris
11. Henny J., Petitclerc C., Fuentes-Arderiu X., Petersen P.H., Queralto J.M., Schiele F., et al. Need for revisiting the concept of reference values. Clin Chem Lab Med 38 (2000) 589-595
12. Faulkner W.R., and Demers L.M. Importance of age-dependent reference values in biochemical testing: are we including the elderly population?. Clin Chem 40 (1994) 855-856
13. Boulat O., Krieg M.A., Janin B., Burckhardt P., Francioli P., and Bachmann C. Clinical chemistry variables in normal elderly and healthy ambulatory populations: comparison with reference values. Clin Chim Acta 272 (1998) 127-135
14. Alehagen U., Goetze J.P., and Dahlström U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta 382 (2007) 8-14
15. Wetzels JFM, Kiemeney L, Swinkels DW, Willems HL, Den Heijer M. Age- and gender-specific reference values of estimated GFR in caucasians: the Nijmegen Biomedical Study. Kidney-international.org [serial online] 2007 May. Available from: URL: http://www.kidney-international.org.
16. Kushida K., Takahashi M., Kawana K., and Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80 (1995) 2447-2450
17. Beck Jensen J.E., Kollerup G., Sorensen H.A., Pors Nielsen S., and Sorensen O.H. A single measurement of biochemical markers of bone turnover has limited utility in the individual person. Scand J Clin Lab Invest 57 (1997) 351-360
18. Delmas P.D. Utilisation clinique des marqueurs biologiques osseux dans l'ostéoporose post-ménopausique. Ann Biol Clin 59 (2001) 299-308
19. Dzien A., Dzien-Bischinger C., and Lechleitner M. Fasting glucose and increasing age. Diabetes Obes Metab 3 (2001) 297-298
20. o 41.
21. Hertoghe T. The multiple hormone deficiency theory of aging. Is human senescence caused mainly by multiple hormone deficiencies?. Ann N Y Acad Sci 1057 (2004) 448-465
22. Giton F., Urien S., Born C., Tichet J., Guéchot J., Callebert J., et al. Determination of bioavailable testosterone [Non-Sex Hormone-Binding globulin (SHBG)-Bound Testosterone] in a population of healthy French men: influence of androstenediol on testosterone binding to SHBG. Clin Chem 53 (2007) 2160-2168
23. Giton F., Fiet J., Guéchot J., Ibrahim F., Bronsard F., Chopin D., et al. Serum bioavailable testosterone: assayed or calculated?. Clin Chem 52 (2006) 474-481
24. Vaninetti S., Baccarelli A., Romoli R., Fanelli M., Faglia G., and Spada A. Effect of aging on serum gonadotropin levels in healthy subjects and patients with non-functioning pituitary adenomas. Eur J Endocrinol 142 (2000) 144-149
25. Fatourechi V. Upper limit of normal serum thyroid-stimulating hormone: a moving and now aging target?. J Clin Endocrinol Metab 92 (2007) 4560-4562
26. Surks M.I., and Hollowell J.G. Age-specific distribution of serum thyrotropin and antihyroid antibodies in the U.S. population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 92 (2007) 4575-4582
27. Epelbaum J., Bassant M.H., Bluet-Pajot M.T., Gourdji D., Jazat-Poindessous F., Kappeler L., et al. Le vieillissement neuroendocrinien. Ann Biol Clin 59 (2001) 437-444
28. Peeters R.P. Thyroid hormones and aging. Hormones 7 (2008) 28-35
29. Nair S.K., Rizza R.A., O'Brien P., Dhatariya K., et al. DHEA in elderly and DHEA or testosterone in elderly men. N Engl J Med 355 (2006) 1647-1659
30. Page S.T., Matsumoto A.M., and Bremner W.J. DHEA and testosterone in the elderly. N Engl J Med 356 (2007) 635
31. Katznelson L., Robinson M.W., Coyle C.L., Lee H., et al. Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men. Eur J Endocrinol 155 (2006) 867-875
32. Liu H., Bravata D.M., Olkin I., Nayak S., et al. Systematic review: the safety and efficacity of growth hormone in the healthy elderly. Ann Intern Med 146 (2007) 104-115
33. Kalish L.A., and McKinlay J.B. Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. Urology 54 (1999) 1022-1027
34. Jones J.S., and Klein E. Four no more: the "PSA cutoff era" is over. Cleve Clin J Med 75 (2008) 30-32
35. Vickers A.J., and Lilja H. Cutpoints in clinical chemistry: time for fundamental reassessment. Clin Chem 55 (2009) 15-17
36. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Scott Lucia M., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4,0 ng per millilitre. N E J Med 350 (2004) 2239-2246
37. Ito K., Yamamoto T., Kubota Y., Suzuki K., Fukabori Y., Kurokawa K., et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 56 (2000) 278-282
38. Loeb S., Roehl K.A., Catalona W.J., and Nadler R.B. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?. BJU Int 101 (2008) 817-821
39. Connolly D., Black A., Murray L.J., Nambirajan T., Keane P.F., and Gavin A. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis. BJU Int 101 (2008) 1507-1512
40. Yamamoto S., Maruyama T., Kondoh N., Nojima M., Takiuchi H., Hirota S., et al. Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml. Int Urol Neprhol 40 (2008) 85-89
41. Sun L., Moul J.W., Hotaling J.M., Rampersaud E., Dahm P., Robertson C., et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged < 50 years. BJU Int 99 (2007) 753-757
42. Nilsson-Ehle H., Jagenburg R., Landahl S., and Svanborg A. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 65 (2000) 297-305
43. Milman N., Pedersen A.N., Ovesen l, and Schroll M. Hemoglobin concentrations in 358 apparently healthy 80-year-old Danish men and women. Should the reference interval be adjusted for age?. Aging Clin Exp Res 20 (2008) 8-14
44. Zakai N.A., Katz R., Hirsch C., Shlipak M.G., et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort. The Cardiovascular Health Study. Arch Intern Med 165 (2005) 2214-2220
45. Chassagne P., Verdonck A., Druesne L., Landrin-Dutot I., et al. La cause d'une anémie normocytaire chez les sujets âgés doit-elle être systématiquement recherchée quelle que soit la valeur de la concentration d'hémoglobine ?. Rev Med Int 25 (2004) 189-194
46. Chaves P.H.M., Xue Q.L., Guralnik J.M., Ferrucci L., Volpato S., and Fried L.P. What constitutes normal haemoglobin concentration in community-dwelling disabled older women?. J Am Geriatr Soc 52 (2004) 1811-1816
47. Marmot M, Banks J, Blundell R, Lessof C, Nazroo J ed. English longitudinal study of ageing - health, wealth and lifestyles of the older population in England: the 2002 English longitudinal study of ageing [serial online] 2003 Dec. Available from: URL: http://www.ifs.org.uk/elsa:report_wavel.php..
48. Nabi H., Kivimaki M., De Vogli R., Marmot M.G., and Singh-Manoux A. Positive and negative affect and risk of coronary heart disease: Whitehall II prospective cohort study. Brit Med J 337 (2008) a118
49. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline. 3rd ed. C28-A3. CLSI - IFCC 2008; 28.